Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M S Mitchell

Showing results (111-120 of 175) with videos related to

Pageof 18
Sort By:
Cancer Chemotherapy Reports|December 1, 1971
Short-term sequential therapy with vinblastine (NSC-49842) and cyclophosphamide (NSC-26271) in Hodgkin's diseaseR C DeConti, M S Mitchell, J C Marsh, et al.
Cancer Research|February 15, 1987
Phase I study of recombinant beta-interferon given by four-hour infusionS M Grunberg, R A Kempf, C L Venturi, et al.
Investigational New Drugs|May 1, 1991
Working conference on biomodulator and chemotherapy combination therapiesT D Brown, M S Mitchell, R Pazdur, et al.
Cancer Research|December 5, 2000
A novel melanoma gene (MG50) encoding the interleukin 1 receptor antagonist and six epitopes recognized by human cytolytic T lymphocytesM S Mitchell, J Kan-Mitchell, B Minev, et al.
Cancer Immunology, Immunotherapy : CII|August 1, 1993
Detection of melanoma-reactive CD4+ HLA-class I-restricted cytotoxic T cell clones with long-term assay and pretreatment of targets with interferon-gammaL G LeMay, J Kan-Mitchell, P Goedegebuure, et al.
Cancer Research|March 1, 1991
Novel gene sequences expressed by human melanoma cells identified by molecular subtractionJ T Hutchins, R J Deans, M S Mitchell, et al.
Journal of the California Dental Association|February 25, 1999
The effect of bioburden on in-depth disinfection of denture base acrylic resinT R Saunders, V L Guillory, S T Gregoire, et al.
Cancer Research|May 1, 1986
Human monoclonal antibodies directed against melanoma tumor-associated antigensJ Kan-Mitchell, A Imam, R A Kempf, et al.
Cancer Immunology, Immunotherapy : CII|January 1, 1992
Low-dose recombinant interleukin-2 and low-dose cyclophosphamide in metastatic breast cancerD V Spicer, A Kelley, R Herman, et al.
Investigational New Drugs|January 1, 1994
Phase II study of low dose cyclophosphamide and intravenous interleukin-2 in metastatic renal cancerW D Quan, G E Dean, G Lieskovsky, et al.
Pageof 18

Showing results (111-120 of 175) with videos related to

Sort By:
Pageof 18
Cancer Chemotherapy Reports|December 1, 1971
Short-term sequential therapy with vinblastine (NSC-49842) and cyclophosphamide (NSC-26271) in Hodgkin's diseaseR C DeConti, M S Mitchell, J C Marsh, et al.
Cancer Research|February 15, 1987
Phase I study of recombinant beta-interferon given by four-hour infusionS M Grunberg, R A Kempf, C L Venturi, et al.
Investigational New Drugs|May 1, 1991
Working conference on biomodulator and chemotherapy combination therapiesT D Brown, M S Mitchell, R Pazdur, et al.
Cancer Research|December 5, 2000
A novel melanoma gene (MG50) encoding the interleukin 1 receptor antagonist and six epitopes recognized by human cytolytic T lymphocytesM S Mitchell, J Kan-Mitchell, B Minev, et al.
Cancer Immunology, Immunotherapy : CII|August 1, 1993
Detection of melanoma-reactive CD4+ HLA-class I-restricted cytotoxic T cell clones with long-term assay and pretreatment of targets with interferon-gammaL G LeMay, J Kan-Mitchell, P Goedegebuure, et al.
Cancer Research|March 1, 1991
Novel gene sequences expressed by human melanoma cells identified by molecular subtractionJ T Hutchins, R J Deans, M S Mitchell, et al.
Journal of the California Dental Association|February 25, 1999
The effect of bioburden on in-depth disinfection of denture base acrylic resinT R Saunders, V L Guillory, S T Gregoire, et al.
Cancer Research|May 1, 1986
Human monoclonal antibodies directed against melanoma tumor-associated antigensJ Kan-Mitchell, A Imam, R A Kempf, et al.
Cancer Immunology, Immunotherapy : CII|January 1, 1992
Low-dose recombinant interleukin-2 and low-dose cyclophosphamide in metastatic breast cancerD V Spicer, A Kelley, R Herman, et al.
Investigational New Drugs|January 1, 1994
Phase II study of low dose cyclophosphamide and intravenous interleukin-2 in metastatic renal cancerW D Quan, G E Dean, G Lieskovsky, et al.
Pageof 18